CiLostAzol for pReventIon of Recurrent sTroke in Africa
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1100 participants.
Also called NCT06919835
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 1,100 participants
- Registry
-
NCT06919835
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Ghana
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT06919835. Randomized; triple masking; primary purpose prevention. Start 2027-01-01 (anticipated); primary completion 2029-07-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- CiLostAzol for pReventIon of Recurrent sTroke in Africa
- Acronym
- CLARITY-Africa
- Condition
- Stroke
- Intervention (Drug)
- Cilostazol 100 mg
- Lead sponsor
- Northern California Institute of Research and Education
Record details
- Record id
cardio:ct-nct06919835- Content hash
b40b677999cc7f88cce37156f67c50f8757e83cc6937128f22a2b24c43203dc2